Product information and disease descriptionPlace of product in therapyDisease description
Epidemiology
55 evidence topics · 43 sources
Hovilpri (pritelivir)
Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults
- Manufacturer
- Asahi Kasei Therapeutics
- Regulatory submission
- NDA submitted February 2026 and approved October 2026
- Last updated